Login +0086-27-65522453 [email protected]

BAW2881 (NVP-BAW2881) Catalog No : 16122733

Chemical Information

Product NameBAW2881 (NVP-BAW2881)
Iupac Chemical NameBAW2881 (NVP-BAW2881) 
Molecular FormulaC22H15F3N4O2 
Molecular Weight424.38 

Technical Data

Appearancecrystalline solid 
SolubilitySoluble in DMSO 
Storage3 years -20ºCpowder 
Shipping ConditionShipped under ambient temperature as non-hazardous chemical. 
Quality control


BAW2881 (NVP-BAW2881) is a novel vascular endothelial growth factor (VEGF) receptor tyrosine-kinase inhibitor that potently inhibits VEGFR1-3 at 1.0-4.3 nanomolar (nM) concentrations and inhibits PDGFR, c-Kit, and RET at 45-72 nM concentrations.NVP-BAW2881 targets the tyrosine kinase domain of murine, porcine, and human VEGFR2. It can be administered both orally and topically, but has not been tested in humans. In vivo studies in VEGF-A transgenic mice showed that oral and topical administration of NVP-BAW2881 strongly reduced psoriasis-like inflammation in ear skin. Histologically, skin lesions in treated mice showed reduced infiltration by leukocytes, reduced epidermal hyperproliferation, normalization of epidermal keratinocyte differentiation, and fewer vascular abnormalities. Vessels in treated mice were smaller in size and fewer in number. In comparison to control mice, treated mice showed significant improvement in ear swelling, skin inflammation, lymph node enlargement, and skin erythema. Though both modes of administration were effective, systemic administration of NVP-BAW2881 was more potent than topical administration. Topical NVP-BAW2881 also effectively reduced VEGF-A-induced vascular permeability in the skin of mice and domestic pigs 

Chemical Structure

16122733 - BAW2881 (NVP-BAW2881) | CAS 861875-60-7


Login to get price

Quick Order


Contact Us